| |  Online-Ressource |
|---|
| Verfasst von: | Haschka, Judith [VerfasserIn]  |
|---|
| | Englbrecht, Matthias [VerfasserIn] |
|---|
| | Hueber, Axel J. [VerfasserIn] |
|---|
| | Manger, Bernhard [VerfasserIn] |
|---|
| | Kleyer, Arnd [VerfasserIn] |
|---|
| | Reiser, Michaela [VerfasserIn] |
|---|
| | Finzel, Stephanie [VerfasserIn] |
|---|
| | Tony, Hans-Peter [VerfasserIn] |
|---|
| | Kleinert, Stefan [VerfasserIn] |
|---|
| | Feuchtenberger, Martin [VerfasserIn] |
|---|
| | Fleck, Martin [VerfasserIn] |
|---|
| | Manger, Karin [VerfasserIn] |
|---|
| | Ochs, Wolfgang [VerfasserIn] |
|---|
| | Schmitt-Haendle, Matthias [VerfasserIn] |
|---|
| | Wendler, Joerg [VerfasserIn] |
|---|
| | Schuch, Florian [VerfasserIn] |
|---|
| | Ronneberger, Monika [VerfasserIn] |
|---|
| | Lorenz, Hanns-Martin [VerfasserIn] |
|---|
| | Nuesslein, Hubert [VerfasserIn] |
|---|
| | Alten, Rieke [VerfasserIn] |
|---|
| | Demary, Winfried [VerfasserIn] |
|---|
| | Henes, Joerg [VerfasserIn] |
|---|
| | Schett, Georg [VerfasserIn] |
|---|
| | Rech, Juergen [VerfasserIn] |
|---|
| Titel: | Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy |
|---|
| Titelzusatz: | interim results from the prospective randomised controlled RETRO study |
|---|
| Verf.angabe: | Judith Haschka, Matthias Englbrecht, Axel J. Hueber, Bernhard Manger, Arnd Kleyer, Michaela Reiser, Stephanie Finzel, Hans-Peter Tony, Stefan Kleinert, Martin Feuchtenberger, Martin Fleck, Karin Manger, Wolfgang Ochs, Matthias Schmitt-Haendle, Joerg Wendler, Florian Schuch, Monika Ronneberger, Hanns-Martin Lorenz, Hubert Nuesslein, Rieke Alten, Winfried Demary, Joerg Henes, Georg Schett, Juergen Rech |
|---|
| Jahr: | 2016 |
|---|
| Jahr des Originals: | 2015 |
|---|
| Umfang: | 7 S. |
|---|
| Fussnoten: | Published online first 6 February 2015 ; Gesehen am 30.04.2020 |
|---|
| Titel Quelle: | Enthalten in: Annals of the rheumatic diseases |
|---|
| Ort Quelle: | London : BMJ Publ. Group, 1939 |
|---|
| Jahr Quelle: | 2016 |
|---|
| Band/Heft Quelle: | 75(2016), 1, Seite 45-51 |
|---|
| ISSN Quelle: | 1468-2060 |
|---|
| Abstract: | Objective To prospectively analyse the risk for disease relapses in patients with rheumatoid arthritis (RA) in sustained remission, either continuing, tapering or stopping disease-modifying antirheumatic drugs (DMARDs) in a prospective randomised controlled trial. - Methods Reduction of Therapy in patients with Rheumatoid arthritis in Ongoing remission is a multicentre, randomised controlled, parallel-group phase 3 trial evaluating the effects of tapering and stopping all conventional and/or biological DMARDs in patients with RA in stable remission. Patients (disease activity score 28 (DAS28)<2.6 for least 6 months) were randomised into three arms, either continuing DMARDs (arm 1), tapering DMARDs by 50% (arm 2) or stopping DMARDs after 6 months tapering (arm 3). The primary endpoint was sustained remission during 12 months. - Results In this interim analysis, the first 101 patients who completed the study were analysed. At baseline, all patients fulfilled DAS28 remission and 70% also American College of Rheumatology- European League Against Rheumatism Boolean remission. 82.2% of the patients received methotrexate, 40.6% biological DMARDs and 9.9% other DMARDs. Overall, 67 patients (66.3%) remained in remission for 12 months, whereas 34 patients (33.7%) relapsed. The incidence of relapses was related to study arms (p=0.007; arm 1: 15.8%; arm 2: 38.9%; arm 3: 51.9%). Multivariate logistic regression identified anticitrullinated protein antibodies (ACPA) positivity (p=0.038) and treatment reduction (in comparison to continuation) as predictors for relapse (arm 2: p=0.012; arm 3: p=0.003). - Conclusions This randomised controlled study testing three different treatment strategies in patients with RA in sustained remission demonstrated that more than half of the patients maintain in remission after tapering or stopping conventional and biological DMARD treatment. Relapses occurred particularly in the first 6 months after treatment reduction and were associated with the presence of ACPA. - Trial registration number 2009-015740-42. |
|---|
| DOI: | doi:10.1136/annrheumdis-2014-206439 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1136/annrheumdis-2014-206439 |
|---|
| | Volltext: https://ard.bmj.com/content/75/1/45 |
|---|
| | DOI: https://doi.org/10.1136/annrheumdis-2014-206439 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Disease Activity |
|---|
| | DMARDs (biologic) |
|---|
| | DMARDs (synthetic) |
|---|
| | Rheumatoid Arthritis |
|---|
| | Treatment |
|---|
| K10plus-PPN: | 1696962439 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy / Haschka, Judith [VerfasserIn]; 2016 (Online-Ressource)
